Physician profile
Logan William Thomas
NPI 1992209514
$6,212.28
in general payments reported to CMS, 2019-2025
24 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $365 · 2023: $2,079 · 2024: $1,953 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,598 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,597.52 |
| Education | $249.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.83 | 2022-2025 | Skyrizi, Botox, Rinvoq |
| Genzyme Corporation | $920.18 | 2022-2025 | |
| Lilly USA, LLC | $780.94 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $476.17 | 2023-2025 | |
| Janssen Biotech, INC. | $447.32 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $397.90 | 2023-2025 | Sotyktu |
| Incyte Corporation | $370.17 | 2022-2025 | Opzelura |
| Ucb, INC. | $367.60 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $326.65 | 2022-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $182.99 | 2023-2025 | |
| Galderma Laboratories, L.P. | $139.04 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.61 | 2022-2024 | Siliq, Duobrii |
| Novartis Pharmaceuticals Corporation | $122.40 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $108.23 | 2024-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $93.02 | 2024-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $67.78 | 2025 | Vtama, Nexplanon |
| Leo Pharma INC. | $53.00 | 2025 | Anzupgo |
| Sun Pharmaceutical Industries INC. | $48.52 | 2023-2024 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.77 | 2024 | Spevigo |
| Organogenesis INC. | $16.98 | 2024 | |
| Journey Medical Corporation | $15.36 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $15.07 | 2023 | Valchlor |
| Verrica Pharmaceuticals INC. | $13.57 | 2024 | Ycanth |
| Biofrontera INC. | $12.18 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.